CO5200770A1 - Transformador de distribucion . - Google Patents
Transformador de distribucion .Info
- Publication number
- CO5200770A1 CO5200770A1 CO00060686A CO00060686A CO5200770A1 CO 5200770 A1 CO5200770 A1 CO 5200770A1 CO 00060686 A CO00060686 A CO 00060686A CO 00060686 A CO00060686 A CO 00060686A CO 5200770 A1 CO5200770 A1 CO 5200770A1
- Authority
- CO
- Colombia
- Prior art keywords
- substituted
- heterocyclyl
- aryl
- nnhr
- co2r
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Un compuesto que tiene la fórmula:<EMI FILE="00060686_1" ID="1" IMF=JPEG >En dondeX-Y-Z se seleccionan de uno de los siguientes:<EMI FILE="00060686_2" ID="2" IMF=JPEG >R1 es H, CONH2, T(n)-R, o T(n) -Ar2;R es un grupo alifático o grupo alifático sustituido;N es cero o uno;T es C(=0), CO2, CONH, S(O)2, S(O)2NH, COCH2 o CH2; cada R2 es independiente seleccionado de hidrógeno, -R, CH2OR, -CH2OH, -CH=O, CH2SR, CH2S(O)R, CH2(C=O)R, CH2CO2, CH2CO2H, CH2CN, CH2NHR, CH2N(R)2, -CH=N-OR, -CH=NNHR, -CH=NNHR, -CH=NN(R)2, -CH=NNHCCOR, -CH=NNHCO2R, -CH=NNHSO2R,-arilo, -arilo sustituido), (-heterociclilo, o -heterociclilo sustituido);Cada R3 es independiente seleccionado de hidrógeno, R, COR, CO2R o S(O)2R;G es R o Ar1;Ar1 es arilo, arilo sustituido, aralquilo, aralquilo sustituido, heterociclilo, o heterociclilo sustituido, en donde Ar1 está opcionalmente fusionado a un anillo de 5 a 7 miembros parcial o completamente insaturado que contiene de 0 a 3 heteroátomos;Q-NH es<EMI FILE="00060686_3" ID="3" IMF=JPEG >en donde el H de Q-NH es opcionalmente reemplazado por R3; A es N o CR3;U es CR3, O S, o NR;Ar2 es arilo, arilo sustituido, heterociclilo, o heterociclilo sustituido, en donde Ar2 está opcionalmente fusionado a un anillo de 5 a 7 miembros parcial o completamente insaturado que contiene de 0 a 3 heteroátomos; yen donde cada átomo de carbono sustituible en Ar2, que incluye el anillo fusionado cuando está presente, es opcional e independiente sustituido por halo, R, OR, SR, OH, NO2, CN, NH2, NHR, N(R)2, NHCOR, NHCONHR, NHCON(R)2, NRCOR, NHCO2R, CO2R, CO2H, COR, CONHR, CON(R)2, S(O)2R, SONH2, S(O)R, SO2NHR, o NHS(O)2R, y en donde cada carbono saturado en el anillo fusionado es además opcional e independientemente sustituido por =O, =S, =NNHR, =NNR2, =N-OR, =NNHCOR, =NNHCO2, =NNHSO2R, o =NR;en donde cada átomo de nitrógeno sustituible en Ar2 es opcionalmente sustituido por R, COR, S(O)2R, o CO2R.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14879599P | 1999-08-13 | 1999-08-13 | |
US16692299P | 1999-11-22 | 1999-11-22 | |
US21151700P | 2000-06-14 | 2000-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5200770A1 true CO5200770A1 (es) | 2002-09-27 |
Family
ID=27386739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00060686A CO5200770A1 (es) | 1999-08-13 | 2000-08-14 | Transformador de distribucion . |
Country Status (22)
Country | Link |
---|---|
US (2) | US6693108B2 (es) |
EP (1) | EP1218369B1 (es) |
JP (1) | JP2003531103A (es) |
KR (1) | KR20020030791A (es) |
CN (1) | CN1222520C (es) |
AR (1) | AR032130A1 (es) |
AT (1) | ATE402163T1 (es) |
AU (1) | AU6909600A (es) |
BR (1) | BR0013551A (es) |
CA (1) | CA2381882C (es) |
CO (1) | CO5200770A1 (es) |
CZ (1) | CZ2002534A3 (es) |
DE (1) | DE60039616D1 (es) |
HK (1) | HK1045507A1 (es) |
HU (1) | HUP0300340A3 (es) |
MX (1) | MXPA02001565A (es) |
MY (1) | MY133159A (es) |
NO (1) | NO20020713L (es) |
NZ (1) | NZ517694A (es) |
PL (1) | PL366110A1 (es) |
SK (1) | SK3572002A3 (es) |
WO (1) | WO2001012621A1 (es) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
EP3222619A1 (en) | 1999-04-15 | 2017-09-27 | Bristol-Myers Squibb Holdings Ireland | Cyclic protein tyrosine kinase inhibitors |
US7119114B1 (en) | 1999-08-19 | 2006-10-10 | Signal Pharmaceuticals, Llc | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto |
US20040072888A1 (en) | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
CA2422377C (en) | 2000-09-15 | 2010-04-13 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
EP1345922B1 (en) | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1364949A4 (en) * | 2001-02-02 | 2005-11-23 | Takeda Pharmaceutical | INHIBITOR OF JNK |
US6987184B2 (en) | 2001-02-15 | 2006-01-17 | Signal Pharmaceuticals, Llc | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related |
JP2005500261A (ja) * | 2001-04-10 | 2005-01-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | Srcおよび他のプロテインキナーゼのインヒビターとしてのイソキサゾール誘導体 |
ATE339416T1 (de) * | 2001-04-13 | 2006-10-15 | Vertex Pharma | Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen |
EP1380576B1 (en) | 2001-04-16 | 2009-11-25 | Eisai R&D Management Co., Ltd. | 1h-indazole compounds inhibiting jnk |
US6787555B2 (en) * | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
US6727364B2 (en) | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
AR035971A1 (es) * | 2001-05-16 | 2004-07-28 | Cephalon Inc | Metodos para el tratamiento y la prevencion del dolor |
US6790846B2 (en) * | 2001-05-24 | 2004-09-14 | The Procter & Gamble Company | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity |
WO2002102800A1 (en) * | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
US6589997B2 (en) * | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
CA2452603A1 (en) * | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
EP1409483B1 (en) | 2001-07-23 | 2008-12-31 | Laboratoires Serono SA | Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
KR20040030941A (ko) * | 2001-08-06 | 2004-04-09 | 파마시아 이탈리아 에스.피.에이. | 키나제 억제제로서 활성인 아미노이속사졸 유도체 |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
EA010859B1 (ru) * | 2001-11-01 | 2008-12-30 | Янссен Фармацевтика Н.В. | Гетероариламины - производные пиримидина и пиридазина в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3) |
MXPA04005427A (es) | 2001-12-10 | 2005-04-19 | Amgen Inc | Ligandos de receptor vainilloide y su uso en tratamientos. |
GB0129476D0 (en) * | 2001-12-10 | 2002-01-30 | Syngenta Participations Ag | Organic compounds |
KR101108722B1 (ko) * | 2002-01-07 | 2012-02-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 데아자퓨린 및 이의 용도 |
AU2003212796A1 (en) * | 2002-01-11 | 2003-07-30 | Vertex Pharmaceuticals Incorporated | Crystal structures of jnk-inhibitor complexes and binding pockets thereof |
ATE530645T1 (de) | 2002-02-12 | 2011-11-15 | Pfizer Prod Inc | Streptomyces avermitilis gen zur regulierung des verhältnisses der b2:b1 avermectine |
JP2005533748A (ja) * | 2002-03-08 | 2005-11-10 | シグナル ファーマシューティカルズ,インコーポレイテッド | 増殖性障害および癌を治療、予防、または管理するための併用療法 |
AU2003247425B2 (en) | 2002-05-22 | 2007-03-08 | Amgen Inc. | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
CN1668733A (zh) * | 2002-05-30 | 2005-09-14 | 细胞基因公司 | 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法 |
IL164209A0 (en) | 2002-05-31 | 2005-12-18 | Eisai Co Ltd | Pyrazole derivatives and pharmaceutical compositions containing the same |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
JP2005538110A (ja) * | 2002-07-29 | 2005-12-15 | ニトロメッド インコーポレーティッド | シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法 |
KR20050032105A (ko) | 2002-08-02 | 2005-04-06 | 버텍스 파마슈티칼스 인코포레이티드 | Gsk-3의 억제제로서 유용한 피라졸 조성물 |
DE10237883A1 (de) * | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
EP1546141A1 (en) * | 2002-09-06 | 2005-06-29 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use in the treatment of ischemic diseases |
US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
WO2004058749A1 (en) | 2002-12-18 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | Benzisoxazole derivatives useful as inhibitors of protein kinases |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
KR101166749B1 (ko) * | 2003-02-11 | 2012-07-27 | 베르날리스(캠브리지)리미티드 | 열쇼크 단백질 저해제로서의 이소옥사졸 화합물 |
GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
JP2006528661A (ja) * | 2003-07-25 | 2006-12-21 | ファイザー・インク | アミノピラゾール化合物およびchk1阻害剤としての使用 |
AR045595A1 (es) * | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
PT1675846E (pt) * | 2003-10-24 | 2010-04-20 | Lilly Co Eli | Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona |
TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
US7276050B2 (en) * | 2004-03-02 | 2007-10-02 | Alan Franklin | Trans-scleral drug delivery method and apparatus |
MXPA06012512A (es) * | 2004-04-28 | 2007-02-08 | Tanabe Seiyaku Co | Compuesto heterociclico. |
TWI326282B (en) * | 2004-04-28 | 2010-06-21 | Mitsubishi Tanabe Pharma Corp | Heterocyclic compound |
US20060018123A1 (en) * | 2004-07-02 | 2006-01-26 | Rose Eric P | Curing light having a reflector |
MX2007002929A (es) * | 2004-09-10 | 2007-08-16 | Syngenta Ltd | Isoxazoles sustituidos como funguicidas. |
PA8649401A1 (es) * | 2004-10-13 | 2006-09-22 | Wyeth Corp | Analogos de anilino-pirimidina |
US7803824B2 (en) | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
US20060094753A1 (en) | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 jnk 억제제 |
BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
US8202889B2 (en) * | 2005-09-09 | 2012-06-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of bacterial IMPDH |
CA2633980A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
EP2008656A1 (en) * | 2007-06-28 | 2008-12-31 | Bergen Teknologioverforing AS | Compositions for the treatment of hyperphenylalaninemia |
WO2009018415A1 (en) | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
AU2009214440B2 (en) | 2008-02-15 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
GB0823002D0 (en) * | 2008-12-17 | 2009-01-28 | Syngenta Participations Ag | Isoxazoles derivatives with plant growth regulating properties |
EP3075730B1 (en) | 2010-06-04 | 2018-10-24 | Genentech, Inc. | Aminopyrimidine derivatives as lrrk2 modulators |
AU2011328139A1 (en) | 2010-11-10 | 2013-04-04 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
JP6903577B2 (ja) * | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ,エルエルシー | 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法 |
CA3210612A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
JP6805232B2 (ja) | 2015-07-24 | 2020-12-23 | セルジーン コーポレイション | (1r,2r,5r)−5−アミノ−2−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体 |
CN105622537A (zh) * | 2016-03-01 | 2016-06-01 | 青岛大学 | 一种3,4,5-三取代异恶唑类化合物的合成方法 |
WO2019155468A1 (en) * | 2018-02-08 | 2019-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
JP2023509260A (ja) | 2019-08-14 | 2023-03-08 | インサイト・コーポレイション | Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物 |
CN115298177A (zh) | 2019-10-11 | 2022-11-04 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
BR112022013169A2 (pt) | 2019-12-30 | 2022-09-13 | Deciphera Pharmaceuticals Llc | Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4876252A (en) * | 1986-01-13 | 1989-10-24 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
DE4408084A1 (de) * | 1994-03-10 | 1995-09-14 | Hoechst Ag | 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US5668148A (en) * | 1995-04-20 | 1997-09-16 | Merck & Co., Inc. | Alpha1a adrenergic receptor antagonists |
EA003925B1 (ru) * | 1997-05-22 | 2003-10-30 | Дж.Д.Сирл Энд Ко | ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p 38 КИНАЗЫ |
US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
-
2000
- 2000-08-11 KR KR1020027001947A patent/KR20020030791A/ko not_active Application Discontinuation
- 2000-08-11 BR BR0013551-8A patent/BR0013551A/pt not_active IP Right Cessation
- 2000-08-11 PL PL00366110A patent/PL366110A1/xx not_active Application Discontinuation
- 2000-08-11 EP EP00957485A patent/EP1218369B1/en not_active Expired - Lifetime
- 2000-08-11 AU AU69096/00A patent/AU6909600A/en not_active Abandoned
- 2000-08-11 NZ NZ517694A patent/NZ517694A/en unknown
- 2000-08-11 JP JP2001517519A patent/JP2003531103A/ja active Pending
- 2000-08-11 MY MYPI20003684 patent/MY133159A/en unknown
- 2000-08-11 MX MXPA02001565A patent/MXPA02001565A/es not_active Application Discontinuation
- 2000-08-11 CZ CZ2002534A patent/CZ2002534A3/cs unknown
- 2000-08-11 DE DE60039616T patent/DE60039616D1/de not_active Expired - Lifetime
- 2000-08-11 WO PCT/US2000/022445 patent/WO2001012621A1/en active IP Right Grant
- 2000-08-11 CA CA2381882A patent/CA2381882C/en not_active Expired - Fee Related
- 2000-08-11 HU HU0300340A patent/HUP0300340A3/hu unknown
- 2000-08-11 AT AT00957485T patent/ATE402163T1/de not_active IP Right Cessation
- 2000-08-11 SK SK357-2002A patent/SK3572002A3/sk unknown
- 2000-08-11 AR ARP000104188A patent/AR032130A1/es not_active Application Discontinuation
- 2000-08-11 CN CNB008141789A patent/CN1222520C/zh not_active Expired - Fee Related
- 2000-08-14 CO CO00060686A patent/CO5200770A1/es not_active Application Discontinuation
-
2002
- 2002-02-12 US US10/074,177 patent/US6693108B2/en not_active Expired - Fee Related
- 2002-02-12 NO NO20020713A patent/NO20020713L/no not_active Application Discontinuation
- 2002-09-23 HK HK02106918.4A patent/HK1045507A1/zh unknown
-
2004
- 2004-02-13 US US10/779,532 patent/US7169798B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ517694A (en) | 2005-03-24 |
HUP0300340A3 (en) | 2005-04-28 |
CZ2002534A3 (cs) | 2002-07-17 |
EP1218369A4 (en) | 2005-06-22 |
US7169798B2 (en) | 2007-01-30 |
SK3572002A3 (en) | 2002-07-02 |
ATE402163T1 (de) | 2008-08-15 |
CA2381882C (en) | 2011-01-25 |
HUP0300340A2 (hu) | 2003-06-28 |
CN1222520C (zh) | 2005-10-12 |
US20030149051A1 (en) | 2003-08-07 |
US20050026967A1 (en) | 2005-02-03 |
AR032130A1 (es) | 2003-10-29 |
KR20020030791A (ko) | 2002-04-25 |
WO2001012621A1 (en) | 2001-02-22 |
CN1378541A (zh) | 2002-11-06 |
MY133159A (en) | 2007-10-31 |
NO20020713L (no) | 2002-04-12 |
AU6909600A (en) | 2001-03-13 |
EP1218369B1 (en) | 2008-07-23 |
HK1045507A1 (zh) | 2002-11-29 |
BR0013551A (pt) | 2003-06-17 |
EP1218369A1 (en) | 2002-07-03 |
CA2381882A1 (en) | 2001-02-22 |
DE60039616D1 (de) | 2008-09-04 |
US6693108B2 (en) | 2004-02-17 |
PL366110A1 (en) | 2005-01-24 |
JP2003531103A (ja) | 2003-10-21 |
NO20020713D0 (no) | 2002-02-12 |
MXPA02001565A (es) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5200770A1 (es) | Transformador de distribucion . | |
PT99135A (pt) | Processo para a preparacao de derivados de piperazina | |
ES2151185T3 (es) | Lipopoliaminas como agentes de transfeccion y sus aplicaciones farmaceuticas. | |
ES2186721T3 (es) | Compuestos de azaindolilideno sustituido y proceso para su preparacion. | |
HUP0001607A2 (hu) | Tienopirimidinszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás ezek előállítására, valamint e vegyületek alkalmazása | |
HUP9700779A1 (hu) | Ösztrogén vegyületek, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ES2087721T3 (es) | Guanidinas sustituidas con (benzodioxano, benzofurano o benzopirano)-alquilamino-alquilo como vasoconstrictores selectivos. | |
ES2188957T3 (es) | N-(4-(heteroarilmetil)fenil)-heteroarilaminas. | |
AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y | |
AR009572A1 (es) | Derivados de 3,4,5,6,7,8-hexahidro pirido (4',3':4,5) tieno (2,3-d) pirimidina sustituidos en posicion 3 y su uso | |
ES488788A0 (es) | Procedimiento de preparacion de una composicion farmaceuticaen particular psicotropa. | |
FI945581A (fi) | Substituoidut (aryylialkoksibentsyyli) aminopropaaniamidijohdannaiset, niiden valmistus ja käyttö antiepileptisinä, neuroprotektiivisina ja antidepressiivisinä aineina | |
PT93360A (pt) | Processo para a preparacao de n-(1,4-benzo-diazepin-3-il)amidas de acidos 1h-indol-2-carboxilicos condensados nas posicoes 1,7 e de composicoes farmaceuticas que as contem | |
ES2108595B1 (es) | Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion. | |
MX9201279A (es) | Derivados de 1-fenil-3-aza bi ciclo alquil-imidazolidin-2-onas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
AR240859A2 (es) | Composicion herbicida que contiene un derivado de difenil eter, dicho compuesto y procedimiento paraprepararlo | |
SU1568887A3 (ru) | Cпocoб пoлучehия пипepaзиhcoдepжaщиx углeboдopoдob или иx kиcлotho-aддиtиbhыx coлeй | |
ES525749A0 (es) | Procedimiento para la preparacion de nuevas 4-fenil-4,5,6,7-tetrahidro-tieno(2,3-c)piridinas sustituidas con radicales basicos | |
CO5170464A1 (es) | Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil- aminometilcromano | |
CO5040091A1 (es) | Derivados de urea | |
ES520312A0 (es) | Procedimiento para la preparacion de 2-aminometilfenoles. | |
ES2192342T3 (es) | 2-(2,6-dioxo-3-fluoropiperidin-3-il)-isoindolinas sustituidas y su uso para reducir los niveles de tnfalfa. | |
ES2135716T3 (es) | Nuevos derivados de glicina, sus compuestos intermedios y composiciones limpiadoras que los comprenden. | |
DK0395527T3 (da) | Imidazobenzodiazepiner og deres salte, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og præparater med indhold deraf | |
CO5011083A1 (es) | Un proceso para preparar analogos de prostaglandina f |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |